Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

被引：342

作者：

Villa, Luisa L.

Ault, Kevin A.

Giuliano, Anna R.

Costa, Ronaldo L. R.

Petta, Carlos A.

Andrade, Rosires P.

Brown, Darron R.

Ferenczy, Alex

Harper, Diane M.

Koutsky, Laura A.

Kurman, Robert J.

Lehtinen, Matti

Malm, Christian

Olsson, Sven-Eric

Ronnett, Brigitte M.

Skjeldestad, Finn Egil

Steinwall, Margareta

Stoler, Mark H.

Wheeler, Cosette M.

Taddeo, Frank J.

Yu, Jimmy

Lupinacci, Lisa

Railkar, Radha

Marchese, Rocio

Esser, Mark T.

Bryan, Janine

Jansen, Kathrin U.

Sings, Heather L.

Tamms, Gretchen M.

Saah, Alfred J.

Barr, Eliav

机构：

[1] Ludwig Inst Canc Res, Dept Virol, BR-01509010 Sao Paulo, SP, Brazil

[2] Univ Iowa, Dept Obstet Gynecol & Epidemiol, Iowa City, IA USA

[3] Univ Arizona, Ctr Canc, Tucson, AZ USA

[4] Inst Brasileiro Controle Canc, Dept Gynecol, Sao Paulo, Brazil

[5] Hosp Canc, Sao Paulo, Brazil

[6] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, Brazil

[7] CERHFAC, Ctr Human Reprod Studies & Clin Trials, Curitiba, Parana, Brazil

[8] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA

[9] McGill Univ, Dept Pathol, Montreal, PQ, Canada

[10] SMBD Jewish Gen Hoso, Montreal, PQ, Canada

[11] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Obstet & Gynecol, Hanover, NH USA

[12] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Community & Family Med, Hanover, NH USA

[13] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA

[14] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

[15] Natl Publ Hlth Inst, Dept Infect Dis Epidemiol, Helsinki, Finland

[16] Danderyd Hosp, Karolinska Inst, Stockholm, Sweden

[17] SINTEF Hlth Res, Dept Epidemiol, Trondheim, Norway

[18] Univ Hosp, Lund, Sweden

[19] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA

[20] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA

[21] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[22] Merck Res Labs, Dept Vaccine, West Point, PA USA

[23] Merck Res Labs, Dept Biol Res, West Point, PA USA

[24] Merck Res Labs, Dept Biostat, West Point, PA USA

[25] Merck Res Labs, Dept Med Commun, West Point, PA USA

[26] Merck Res Labs, Dept Biol Clin Res, West Point, PA USA

来源：

VACCINE | 2006年 / 24卷 / 27-28期

关键词：

human papillomavirus; vaccine; immunogenicity;

D O I：

10.1016/j.vaccine.2006.04.068

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：5571 / 5583

页数：13

共 36 条

[1] A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine [J].

Ault, KA ;

Giuliano, AR ;

Edwards, RP ;

Tamms, G ;

Kim, LL ;

Smith, JF ;

Jansen, KU ;

Allende, M ;

Taddeo, FJ ;

Skulsky, DM ;

Barr, E .

VACCINE, 2004, 22 (23-24) :3004-3007

[2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[3] Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine [J].

Brown, DR ;

Fife, KH ;

Wheeler, CM ;

Koutsky, LA ;

Lupinacci, LM ;

Railkar, R ;

Suhr, G ;

Barr, E ;

Dicello, A ;

Li, WL ;

Smith, JF ;

Tadesse, A ;

Jansen, KU .

VACCINE, 2004, 22 (21-22) :2936-2942

[4] Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer [J].

Brown, DR ;

Bryan, JT ;

Schroeder, JM ;

Robinson, TS ;

Fife, KH ;

Wheeler, CM ;

Barr, E ;

Smith, PR ;

Chiacchierini, L ;

DiCello, A ;

Jansen, KU .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (09) :1183-1186

[5]

*CDC, GEN HPV INF

[6] MONOCLONAL ANTIBODY-MEDIATED NEUTRALIZATION OF INFECTIOUS HUMAN PAPILLOMAVIRUS TYPE-11 [J].

CHRISTENSEN, ND ;

KREIDER, JW ;

CLADEL, NM ;

PATRICK, SD ;

WELSH, PA .

JOURNAL OF VIROLOGY, 1990, 64 (11) :5678-5681

[7] Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6 [J].

Christensen, ND ;

Reed, CA ;

Cladel, NM ;

Hall, K ;

Leiserowitz, GS .

VIROLOGY, 1996, 224 (02) :477-486

[8] Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies [J].

Christensen, ND ;

Dillner, J ;

Eklund, C ;

Carter, JJ ;

Wipf, GC ;

Reed, CA ;

Cladel, NM ;

Galloway, DA .

VIROLOGY, 1996, 223 (01) :174-184

[9] Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. [J].

Clifford, GM ;

Rana, RK ;

Franceschi, S ;

Smith, JS ;

Gough, G ;

Pimenta, JM .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1157-1164

[10] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 [J].

Dias, D ;

Van Doren, J ;

Schlottmann, S ;

Kelly, S ;

Puchalski, D ;

Ruiz, W ;

Boerckel, P ;

Kessler, J ;

Antonello, JM ;

Green, T ;

Brown, M ;

Smith, J ;

Chirmule, N ;

Barr, E ;

Jansen, KU ;

Esser, MT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) :959-969

← 1 2 3 4 →